Diabetes

Merck Announces First-Quarter 2022 Dividend

Tuesday, November 30, 2021 - 7:48pm

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.69 per share of the companys common stock for the first quarter of 2022.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.69 per share of the companys common stock for the first quarter of 2022.
  • Payment will be made on Jan. 7, 2022 to shareholders of record at the close of business on Dec. 15, 2021.
  • We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships.
  • Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
    This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the company) includes forward-looking statements within the meaning of the safe harbor provisions of the U.S.

Digital Healthcare Market to grow US$ 7,304.3 Mn by end of 2028, Says Coherent Market Insights

Tuesday, November 30, 2021 - 6:10pm

SEATTLE, Nov. 30, 2021 /PRNewswire/ -- According to Coherent Market Insights, The global digital healthcare market is estimated to account for US$ 7,304.3 Mn in terms of value by the end of 2028.

Key Points: 
  • SEATTLE, Nov. 30, 2021 /PRNewswire/ -- According to Coherent Market Insights, The global digital healthcare market is estimated to account for US$ 7,304.3 Mn in terms of value by the end of 2028.
  • This article will discuss what digital healthcare is and how it is different from traditional healthcare.
  • Moreover, launch of healthcare digital devices is also expected to aid in growth of the global digital healthcare market over the forecast period.
  • Middle East is expected to witness significant growth in the global digital healthcare market, owing to increasing adoption of digital healthcare in the region.

Digital Healthcare Market to grow US$ 7,304.3 Mn by end of 2028, Says Coherent Market Insights

Tuesday, November 30, 2021 - 6:10pm

SEATTLE, Nov. 30, 2021 /PRNewswire/ -- According to Coherent Market Insights, The global digital healthcare market is estimated to account for US$ 7,304.3 Mn in terms of value by the end of 2028.

Key Points: 
  • SEATTLE, Nov. 30, 2021 /PRNewswire/ -- According to Coherent Market Insights, The global digital healthcare market is estimated to account for US$ 7,304.3 Mn in terms of value by the end of 2028.
  • This article will discuss what digital healthcare is and how it is different from traditional healthcare.
  • Moreover, launch of healthcare digital devices is also expected to aid in growth of the global digital healthcare market over the forecast period.
  • Middle East is expected to witness significant growth in the global digital healthcare market, owing to increasing adoption of digital healthcare in the region.

Global Ultrasonic Electrosurgical Devices (Consumables, Generators) Market Analysis & Forecasts, 2017-2020 & 2021-2028 - ResearchAndMarkets.com

Tuesday, November 30, 2021 - 4:25pm

The global ultrasonic electrosurgical devices market size is expected to reach USD 5.45 billion by 2028 and is expected to expand at a CAGR of 5.04% from 2021 to 2028.

Key Points: 
  • The global ultrasonic electrosurgical devices market size is expected to reach USD 5.45 billion by 2028 and is expected to expand at a CAGR of 5.04% from 2021 to 2028.
  • Furthermore, the increasing incidence of cancer across the globe is predicted to boost the demand for ultrasonic electrosurgical devices.
  • Several manufacturers are focusing on developing technologically advanced ultrasonic electrosurgical devices to maintain a strong market presence.
  • Ultrasonic Electrosurgical Devices Market Variables, Trends & Scope

Palomar Health Partners With Kara Health to Form Joint Venture: Palomar Health Palliative & Hospice Care

Tuesday, November 30, 2021 - 4:30pm

Palomar Health is partnering with Kara Health to expand its continuum of care, further allowing patients to receive world-class healthcare in their own community and home through a new joint venture Palomar Health Palliative & Hospice Care .

Key Points: 
  • Palomar Health is partnering with Kara Health to expand its continuum of care, further allowing patients to receive world-class healthcare in their own community and home through a new joint venture Palomar Health Palliative & Hospice Care .
  • Through this new partnership, Palomar Health Palliative & Hospice Care allows patients to stay within the Palomar Health family when dealing with serious illness.
  • This joint venture shows Palomar Healths commitment to providing dignified care through end of life to our communities, Palomar Health Chief Operations Officer Sheila Brown said.
  • Founded in 2017 and headquartered in Beverly Hills, CA, Kara Health is a tech-enabled homecare company that specializes in palliative and hospice care.

CareSimple® Awarded Remote Patient Monitoring Agreement with Premier

Tuesday, November 30, 2021 - 3:00pm

PALM BEACH, Fla., Nov. 30, 2021 /PRNewswire/ -- CareSimple , the platform simplifying remote patient monitoring (RPM) for virtually all patients, has been awarded a group purchasing agreement with Premier , a leading healthcare improvement company.

Key Points: 
  • PALM BEACH, Fla., Nov. 30, 2021 /PRNewswire/ -- CareSimple , the platform simplifying remote patient monitoring (RPM) for virtually all patients, has been awarded a group purchasing agreement with Premier , a leading healthcare improvement company.
  • Premier is uniting an alliance of approximately 4,400 U.S. hospitals and 225,000 other providers to transform healthcare.
  • Under the terms of this new relationship, CareSimple will now be available to Premier members in the RPM category, which includes suppliers of technology that enable remote monitoring of patients in clinical settings or at the home, which may increase access to care and decrease healthcare delivery costs.
  • CareSimple is an easy-to-use, secure, and scalable way to offer Remote Patient Monitoring (RPM) to at-risk patient populations.

Vida Health Adds Tech and Healthcare Leaders to Board of Directors

Tuesday, November 30, 2021 - 2:18pm

Skip is legendary in Silicon Valley for his leadership and insight, and were excited to continue to learn from his experience.

Key Points: 
  • Skip is legendary in Silicon Valley for his leadership and insight, and were excited to continue to learn from his experience.
  • A veteran Silicon Valley leader, Battle has also served on the board for several high-profile companies including Netflix, LinkedIn, Expedia, OpenTable, FICO, and Workday.
  • Vida has full-stack virtual healthcare solutions for chronic mental and physical health conditions in both English and Spanish and serves members in all 50 states.
  • Vida Health is a virtual care company intentionally designed to treat mental and physical conditions together.

AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001

Tuesday, November 30, 2021 - 1:30pm

AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ImStem Biotechnology, Inc. (ImStem), a biopharmaceutical company developing human embryonic stem cell (ESC)-derived mesenchymal stem cells, has dosed the first U.S. multiple sclerosis (MS) patient with ImStems lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA. IMS001 was derived by ImStem from AgeXs pluripotent stem cell line designated ESI-053, under a non-exclusive sublicense from AgeX.

Key Points: 
  • AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ImStem Biotechnology, Inc. (ImStem), a biopharmaceutical company developing human embryonic stem cell (ESC)-derived mesenchymal stem cells, has dosed the first U.S. multiple sclerosis (MS) patient with ImStems lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA. IMS001 was derived by ImStem from AgeXs pluripotent stem cell line designated ESI-053, under a non-exclusive sublicense from AgeX.
  • AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics to treat human diseases to increase healthspan and combat the effects of aging.
  • AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.
  • ImStem Biotechnology Inc. is a privately held company headquartered in Farmington, CT. For more information, visit www.imstem.com .

Anji Pharma Fully Enrolls Cohort at Leading Beijing Hospital to Ready Global ANJ900 Pivotal Program in Asia

Tuesday, November 30, 2021 - 2:00pm

Anji Pharma (Anji), an emerging global medicines company, today announced full enrollment for a confirmatory study in Chinese healthy participants for a delayed-release formulation of metformin called ANJ900.

Key Points: 
  • Anji Pharma (Anji), an emerging global medicines company, today announced full enrollment for a confirmatory study in Chinese healthy participants for a delayed-release formulation of metformin called ANJ900.
  • Anji plans to report topline data from this study in January 2022.
  • The full enrollment of the Beijing study is an important milestone for our DREAM-T2D program and our multi-national clinical operations organization, noted Greg Dombal, Anjis Global Head of Development.
  • Anji Pharma is a clinical-stage company dedicated to bringing life-changing therapies to patients across the globe.

Virtis Health Unveils Infusion Centers to Serve Patients in Dallas/Fort Worth and Surrounding Communities

Tuesday, November 30, 2021 - 2:00pm

Virtis Health Dallas/Fort Worth (DFW) offers a range of therapy management services and treatments for patients with autoimmune disorders, including chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis and myasthenia gravis.

Key Points: 
  • Virtis Health Dallas/Fort Worth (DFW) offers a range of therapy management services and treatments for patients with autoimmune disorders, including chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis and myasthenia gravis.
  • Virtis Health DFW reaches patients in the Dallas-Fort Worth metroplex and is conveniently located at 2912 W 6th Street, Suite 120, Fort Worth, Texas, 76107, 817.717.2854.
  • Virtis Health DFW delivers services and care in private rooms and offers patients a range of amenities.
  • A licensed, advanced nurse practitioner supervises the Virtis Health DFW infusion center clinical practice and can assess, diagnose, treat and manage general and chronic illnesses.